record initialized not assigned to examiner
on 09 Feb 2024
Last Applicant/ Owned by
Ole Maaløes Vej 3
Copenhagen N
DK
DK-2200
Serial Number
98394985 filed on 06th Feb 2024
Registration Number
N/A
Correspondent Address
BRYCE J. MAYNARD
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
The color(s) blue and purple is/are claimed as a feature of the mark. Pharmaceutical preparations for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune systemRead More
Pharmaceutical preparations for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; synthetic peptides for pharmaceutical use for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; vaccines
No 98394985
No Service/Collective Mark
No
Yes
Yes
No
No
No
No
No
No
26.01.09 -
Geometric figures, objects, humans, plants or animals forming or bordering the perimeter of a circle
26.01.21 -
Circles that are totally or partially shaded
26.01.31 -
Five or more circles
The mark consists of the stylized wording CYLEMBIO in blue with a circle made up of ten circles of varying sizes in varying shades of blue and purple in a circular pattern above the letter "I".
Status Date | Action Taken |
---|---|
15th Mar 2024 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
14th Mar 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
09th Feb 2024 | NEW APPLICATION ENTERED |